AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca FluMist / Fluenz (influenza vaccine) by Quarter
FluMist / Fluenz (influenza vaccine) — Emerging Markets product sales ($M) ($M)
AstraZeneca FluMist / Fluenz (influenza vaccine): $1M in Q2 2026.
Latest, Q2 2026
1
Period ended Jun 30, 2026
Change on a year earlier
–
0 in Q2 2025
History
23 quarters
Since Q4 2020
Sources
23
Documents cited below
Where the Q2 2026 figure comes from
“|| FluMist | | 18 | | 79 | | 78 | | ( 2 ) | | n/m | | 1 | | n/m | | n/m | | - | | - | | - | | 19 | | 90 | | 82”
Source: Form 6-K FY2026Q2 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). AstraZeneca FluMist / Fluenz (influenza vaccine) ($M), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-flumist-em
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.